Roxadustat + Epoetin alfa + Darbepoetin alfa + Iron
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anemia
Conditions
Anemia, End Stage Renal Disease (ESRD)
Trial Timeline
Nov 21, 2014 → Jul 6, 2018
NCT ID
NCT02278341About Roxadustat + Epoetin alfa + Darbepoetin alfa + Iron
Roxadustat + Epoetin alfa + Darbepoetin alfa + Iron is a phase 3 stage product being developed by Astellas Pharma for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02278341. Target conditions include Anemia, End Stage Renal Disease (ESRD).
What happened to similar drugs?
20 of 20 similar drugs in Anemia were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02278341 | Phase 3 | Completed |
Competing Products
20 competing products in Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aranesp® | Amgen | Approved | 43 |
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| LY2787106 | Eli Lilly | Phase 1 | 29 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 40 |
| epoetin beta + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| recombinant human erythropoietin + recombinant human erythropoietin placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| recombinant human erythropoietin + recombinant human erythropoietin | Chugai Pharmaceutical | Phase 3 | 40 |
| darbepoetin alfa | Amgen | Phase 3 | 40 |
| Prasugrel | Daiichi Sankyo | Phase 1 | 29 |
| Prasugrel + Placebo | Daiichi Sankyo | Phase 2 | 35 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| roxadustat | Astellas Pharma | Phase 3 | 40 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |
| Alefacept | Astellas Pharma | Phase 1 | 21 |
| Roxadustat | Astellas Pharma | Phase 2 | 35 |
| roxadustat | Astellas Pharma | Phase 1 | 29 |
| Roxadustat + Placebo | Astellas Pharma | Phase 3 | 40 |
| Roxadustat | Astellas Pharma | Pre-clinical | 26 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 40 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 40 |